Georgantas Robert William III
Known title: Chief Scientific OfficerCIK: 0001827728
Associated companies
Transaction History
| BDSX | ▲ Buy | Grant | 12,000 | $14K | 11/21/2022 | View on chart |
| BDSX | ▼ Sell | Open Market | 785 | $799 | 11/10/2022 | View on chart |
| BDSX | ▼ Sell | Open Market | 991 | $1K | 11/9/2022 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 5,646 | — | 11/8/2022 | View on chart |
| BDSX | ▼ Sell | Open Market | 1,686 | $4K | 8/9/2022 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 5,647 | — | 8/8/2022 | View on chart |
| BDSX | ▼ Sell | Open Market | 2,004 | $4K | 5/10/2022 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 5,647 | — | 5/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships
Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.